Ugo Consoli
Overview
Explore the profile of Ugo Consoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bellofiore C, Benvenuti P, Mina R, Basset M, Foli A, Nanci M, et al.
Hematol Oncol
. 2024 Jun;
42(4):e3289.
PMID: 38824453
Daratumumab-based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real-world data on daratumumab efficacy in...
2.
Giuffrida G, Markovic U, Condorelli A, Duminuco A, Calafiore V, Conticello C, et al.
Eur J Haematol
. 2023 Sep;
111(6):922-929.
PMID: 37747757
Background: Gaucher disease (GD) is a rare autosomal recessive inherited disorder caused by the lysosomal enzyme acid β-glucosidase deficiency. Many patients experience a critical delay in the diagnosis of up...
3.
Innao V, Calogero R, Lo Presti F, Consoli U
Case Rep Hematol
. 2023 Jun;
2023:9953245.
PMID: 37323813
Immune thrombocytopenia (ITP) is immune-mediated platelet loss due to increased destruction and insufficient production. Treatment guidelines provide for first-line steroid-based therapies followed by thrombopoietin receptor agonists (TPO-RAs) and fostamatinib for...
4.
Napolitano M, Vianelli N, Ghiotto L, Cantoni S, Carli G, Carpenedo M, et al.
Mediterr J Hematol Infect Dis
. 2023 Mar;
15(1):e2023019.
PMID: 36908864
Background: Two thrombopoietin receptor agonists (TPO-RA), romiplostim and eltrombopag, are currently widely adopted as second-line ITP therapy even in the absence of robust evidence on their comparative advantages over rituximab...
5.
Marino A, Calvo M, Trovato L, Scalia G, Gussio M, Consoli U, et al.
Pathogens
. 2023 Feb;
12(2).
PMID: 36839576
Hematological diseases, especially those causing severe neutropenia, represent the main factor in the development of invasive fungal infections (IFIs). Furthermore, COVID-19 has been considerably associated with IFIs due to immunological...
6.
Bruzzese A, Derudas D, Galli M, Martino E, Rocco S, Conticello C, et al.
Hematol Oncol
. 2022 May;
40(4):704-715.
PMID: 35608183
The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple...
7.
Petrini M, Gaidano G, Mengarelli A, Consoli U, Santoro A, Liberati A, et al.
Adv Hematol
. 2022 Feb;
2022:5581772.
PMID: 35126524
Subcutaneous (SC) rituximab may be beneficial in terms of convenience and tolerability, with potentially fewer and less severe administration-related reactions (ARRs) compared to the intravenous (IV) form. This report presents...
8.
Innao V, Urso S, Insalaco M, Borraccino A, Consoli U
Thromb Res
. 2022 Jan;
210:91-93.
PMID: 35033862
No abstract available.
9.
Costanzo R, Scalia G, Marrone S, Umana G, Giuffrida M, Furnari M, et al.
Surg Neurol Int
. 2021 Sep;
12:387.
PMID: 34513154
Background: Burkitt's lymphoma is a non-Hodgkin B-cell lymphoma, occurring mostly in Equatorial Africa. According to the WHO, classification is three different variants: sporadic, endemic, and immunodeficient-associated. Here, we present a...
10.
Santoro A, Mazza R, Spina M, Califano C, Specchia G, Carella M, et al.
Ann Hematol
. 2021 Jul;
100(10):2547-2556.
PMID: 34327561
We investigated the feasibility and activity of an intensified dose-dense ABVD (dd-ABVD) regimen in patients with early-stage unfavorable Hodgkin lymphoma (HL). This prospective, multicenter, phase II study enrolled 96 patients...